Therapy of Angiosarcoma with Thalidomide and Lenalidomide

Angiosarcoma is an uncommon malignancy with a poor prognosis. Systemic therapy options for patients with metastatic disease generally have limited effectiveness. In this case study, a 73-year-old male with metastatic angiosarcoma who previously declined chemotherapy and developed progressive disease...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	M. Jules Mattes, Jeffrey A. Mattes, Roman Groisberg, Malcolm D. Mattes
Formato:	article
Lenguaje:	EN
Publicado:	Karger Publishers 2021
Materias:	angiosarcoma lenalidomide thalidomide Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/11781034e0c34366bdad1c958c3619c5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:11781034e0c34366bdad1c958c3619c5
record_format	dspace
spelling	oai:doaj.org-article:11781034e0c34366bdad1c958c3619c52021-12-02T12:40:23ZTherapy of Angiosarcoma with Thalidomide and Lenalidomide1662-657510.1159/000519970https://doaj.org/article/11781034e0c34366bdad1c958c3619c52021-11-01T00:00:00Zhttps://www.karger.com/Article/FullText/519970https://doaj.org/toc/1662-6575Angiosarcoma is an uncommon malignancy with a poor prognosis. Systemic therapy options for patients with metastatic disease generally have limited effectiveness. In this case study, a 73-year-old male with metastatic angiosarcoma who previously declined chemotherapy and developed progressive disease after checkpoint inhibitor immunotherapy elected to try thalidomide based on 6 case reports describing its effectiveness. Thalidomide resulted in stable disease for 9 months, but due to severe neuropathy as a side effect, lenalidomide was then substituted for thalidomide. The patient continued to have stable disease on lenalidomide for an additional 16 months and ongoing. This is the first case study to report on effective treatment of angiosarcoma with lenalidomide. Further investigation of lenalidomide in the management of angiosarcoma is warranted.M. Jules MattesJeffrey A. MattesRoman GroisbergMalcolm D. MattesKarger PublishersarticleangiosarcomalenalidomidethalidomideNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCase Reports in Oncology, Vol 14, Iss 3, Pp 1580-1585 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	angiosarcoma lenalidomide thalidomide Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	angiosarcoma lenalidomide thalidomide Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 M. Jules Mattes Jeffrey A. Mattes Roman Groisberg Malcolm D. Mattes Therapy of Angiosarcoma with Thalidomide and Lenalidomide
description	Angiosarcoma is an uncommon malignancy with a poor prognosis. Systemic therapy options for patients with metastatic disease generally have limited effectiveness. In this case study, a 73-year-old male with metastatic angiosarcoma who previously declined chemotherapy and developed progressive disease after checkpoint inhibitor immunotherapy elected to try thalidomide based on 6 case reports describing its effectiveness. Thalidomide resulted in stable disease for 9 months, but due to severe neuropathy as a side effect, lenalidomide was then substituted for thalidomide. The patient continued to have stable disease on lenalidomide for an additional 16 months and ongoing. This is the first case study to report on effective treatment of angiosarcoma with lenalidomide. Further investigation of lenalidomide in the management of angiosarcoma is warranted.
format	article
author	M. Jules Mattes Jeffrey A. Mattes Roman Groisberg Malcolm D. Mattes
author_facet	M. Jules Mattes Jeffrey A. Mattes Roman Groisberg Malcolm D. Mattes
author_sort	M. Jules Mattes
title	Therapy of Angiosarcoma with Thalidomide and Lenalidomide
title_short	Therapy of Angiosarcoma with Thalidomide and Lenalidomide
title_full	Therapy of Angiosarcoma with Thalidomide and Lenalidomide
title_fullStr	Therapy of Angiosarcoma with Thalidomide and Lenalidomide
title_full_unstemmed	Therapy of Angiosarcoma with Thalidomide and Lenalidomide
title_sort	therapy of angiosarcoma with thalidomide and lenalidomide
publisher	Karger Publishers
publishDate	2021
url	https://doaj.org/article/11781034e0c34366bdad1c958c3619c5
work_keys_str_mv	AT mjulesmattes therapyofangiosarcomawiththalidomideandlenalidomide AT jeffreyamattes therapyofangiosarcomawiththalidomideandlenalidomide AT romangroisberg therapyofangiosarcomawiththalidomideandlenalidomide AT malcolmdmattes therapyofangiosarcomawiththalidomideandlenalidomide
_version_	1718393724621291520

Therapy of Angiosarcoma with Thalidomide and Lenalidomide

Ejemplares similares